Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3985297 · 1 trial · 1 indication
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY3985297 (Cohorts 1-8) | EXPERIMENTAL | Single ascending dose of LY3985297 administered either intravenously (IV) or subcutaneously (SC). Cohort 5,6 and 7 is conducted in Japanese or Chinese participants. |
| Part B: LY3985297 (Cohorts 1-4) | EXPERIMENTAL | Multiple ascending dose of LY3985297 administered either IV or SC. |
| Placebo Comparator: Part A and B: Placebo | PLACEBO_COMPARATOR | Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3985297 | DRUG | Administered either IV or SC. |
| Placebo | DRUG | Administered either IV or SC. |
Inclusion Criteria: * Participants must be overtly healthy, as determined by medical evaluation. * Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, and a minimum body weight of 45.0 kg. * Participants must be assigned male or female at birth and not of childbear...
LY3985297 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other. As an investigational drug, it is not yet approved and remains in clinical development.
LY3985297 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational small molecule in healthy participants.
LY3985297 is in Phase 1 clinical development. A first-in-human study of the drug in healthy participants has been completed. The drug is investigational and has not been approved by regulatory authorities. It is still in the early stages of clinical testing.
LY3985297 has one completed clinical trial, identified as NCT06395012, titled "A First-In-Human Study of LY3985297 in Healthy Participants." This Phase 1 study enrolled 140 participants in the United States. The trial was randomized, double-blind, and placebo-controlled, and it included healthy volunteers aged 18 years and older.
LY3985297 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A first-in-human study in healthy participants has been completed, but the drug has not yet received regulatory approval. It remains in clinical development and is not available for commercial use.